Moody Aldrich Partners’s Cytokinetics CYTK Stock Holding History

Moody Aldrich Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.47M	Sell	28,963 -7,982	-22%	-$573K	0.44%	96
2026 Q1	$2.44M	Sell	36,945 -41,673	-53%	-$2.65M	0.44%	99
2025 Q4	$5M	Sell	78,618 -3,842	-5%	-$239K	0.93%	37
2025 Q3	$4.53M	Buy	+82,460	New	+$3.4M	0.86%	50
2024 Q4	–	Sell	-46,731	Closed	-$2.47M	–	208
2024 Q3	$2.47M	Sell	46,731 -23,174	-33%	-$1.29M	0.45%	86
2024 Q2	$3.79M	Sell	69,905 -2,992	-4%	-$181K	0.74%	63
2024 Q1	$5.11M	Buy	72,897 +43,026	+144%	+$3.33M	0.87%	43
2023 Q4	$2.49M	Sell	29,871 -64,577	-68%	-$2.34M	0.45%	83
2023 Q3	$2.78M	Buy	94,448 +5,172	+6%	+$172K	0.53%	72
2023 Q2	$2.91M	Sell	89,276 -270	-0.3%	-$9.99K	0.57%	72
2023 Q1	$3.15M	Sell	89,546 -3,287	-4%	-$134K	0.64%	68
2022 Q4	$4.25M	Sell	92,833 -2,257	-2%	-$97.1K	0.86%	52
2022 Q3	$4.61M	Sell	95,090 -44,086	-32%	-$2.12M	0.95%	44
2022 Q2	$5.47M	Buy	139,176 +44,620	+47%	+$1.8M	1.07%	36
2022 Q1	$3.48M	Buy	94,556 +10,007	+12%	+$356K	0.49%	72
2021 Q4	$3.85M	Sell	84,549 -15,631	-16%	-$603K	0.54%	73
2021 Q3	$3.58M	Buy	+100,180	New	+$2.95M	0.45%	80

Other funds holding CYTK

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Moody Aldrich Partners's CYTK Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Cytokinetics (CYTK) stake by 22% in Q2 2026, selling an estimated $573K and leaving 28,963 shares worth $2.47M. The position accounts for 0.44% of the portfolio, ranked #96.

Moody Aldrich Partners first reported a position in CYTK in Q3 2021 and has held it in 17 quarters since. The position peaked at $5.47M in Q2 2022. 35 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Moody Aldrich Partners held 28,963 shares of Cytokinetics worth $2.47M as of Q2 2026.
Moody Aldrich Partners sold 7,982 Cytokinetics shares in Q2 2026, an estimated $573K.
Cytokinetics made up 0.44% of Moody Aldrich Partners's portfolio in Q2 2026, its #96 holding.
Moody Aldrich Partners first reported a position in Cytokinetics in Q3 2021 and has held it in 17 quarters since.
Moody Aldrich Partners's Cytokinetics position peaked at $5.47M in Q2 2022.
35 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.